Validation of high-throughput, semiquantitative solid-phase SARS coronavirus-2 serology assays in serum and dried blood spot matrices.
Bioanalysis
; 13(15): 1183-1193, 2021 Aug.
Article
in English
| MEDLINE | ID: covidwho-1266825
ABSTRACT
Aim:
Serological assays for the detection of anti-SARS coronavirus-2 (SARS-CoV-2) antibodies are essential to the response to the global pandemic. A ligand binding-based serological assay was validated for the semiquantitative detection of IgG, IgM, IgA and neutralizing antibodies (nAb) against SARS-CoV-2 in serum.Results:
The assay demonstrated high levels of diagnostic specificity and sensitivity (85-99% for all analytes). Serum IgG, IgM, IgA and nAb correlated positively (R2 = 0.937, R2 = 0.839, R2 = 0.939 and R2 = 0.501, p < 0.001, respectively) with those measured in dried blood spot samples collected using the hemaPEN® microsampling device (Trajan Scientific and Medical, Victoria, Australia). In vitro SARS-CoV-2 pseudotype neutralization correlated positively with the solid phase nAb signals in convalescent donors (R2 = 0.458, p < 0.05).Conclusion:
The assay is applicable in efficacy studies, infection monitoring and postmarketing surveillance following vaccine rollout.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
High-Throughput Screening Assays
/
Dried Blood Spot Testing
/
SARS-CoV-2
/
COVID-19
Type of study:
Diagnostic study
/
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Bioanalysis
Year:
2021
Document Type:
Article
Affiliation country:
Bio-2021-0065
Similar
MEDLINE
...
LILACS
LIS